ArticleInternational journal of particle therapy2026
Evaluation of Magnetic Resonance Imaging-Derived Synthetic Computed Tomography in Prostate Cancer Carbon Ion Radiotherapy: Impact of Fixation Shell.
Article in International journal of particle therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Magnetic resonance imaging (MRI) offers superior soft-tissue contrast for prostate delineation, and MR-only radiotherapy eliminates computed tomography (CT)-MRI registration errors. Although synthetic CT (sCT) has been validated for photon and proton therapy, its clinical feasibility in carbon ion radiotherapy (CIRT) remains unclear, particularly because dose accuracy in CIRT is highly sensitive to stopping-power ratio (SPR) errors. This study evaluated the dosimetric accuracy of MRI-derived sCT for prostate CIRT, including the effect of a thermoplastic fixation shell used clinically but not visualized on MRI. Methods: Twenty patients with prostate cancer underwent same-day planning CT (pCT) and MRI. sCT images were generated using the MRCAT algorithm (Philips Healthcare). Bone pseudo-Hounsfield units were replaced with institution-specific SPR values to improve range accuracy. Treatment plans were created on the pCT and recalculated on the sCT using identical beam parameters. Dose agreement was assessed using carbon-ion depth and lateral dose profiles, 3D gamma analysis (3%/3 mm, 2%/2 mm, 1%/1 mm), and key Dose-volume histogram indices. To evaluate the fixation-shell impact, a 3-mm virtual shell was added to the sCT and compared with a corresponding pCT containing the physical shell. Results: The sCT-based distal range was longer than that of the pCT by 2.7 ± 1.6 mm, reduced to 1.2 ± 1.6 mm with shell inclusion. Lateral dose differences were <1 mm for all patients. Gamma passing rates exceeded 90% for 2%/2 mm and 3%/3 mm criteria, and the 1%/1 mm pass rate at the 50% threshold improved by ∼6% with shell inclusion. CTV D99% and PTV D1% agreed within ±1%, whereas PTV D95% decreased by up to 8% at the target periphery. Organs at risk (OAR) dose differences were clinically negligible. Conclusions: With bone SPR adjustment and fixation-shell consideration, Magnetic Resonance for Calculating ATtenuation-based sCT provides clinically acceptable dose-calculation accuracy for prostate CIRT, supporting the feasibility of MR-only planning.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.